Volume 11, Issue 2 (6-2022)                   JCHR 2022, 11(2): 137-141 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Taheri Soodejani M, Hosseini S, Sefidkar R, Madadizadeh F, Fallahzadeh H, Dehghan A, et al . Comorbidity and its Impact on Mortality of COVID-19 in Yazd Province, a Central Part of Iran: a Hospital-Based Study. JCHR 2022; 11 (2) :137-141
URL: http://jhr.ssu.ac.ir/article-1-894-en.html
1- Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of public health, ShahidSadoughi University of Medical Sciences, Yazd, Iran
2- Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of public health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
3- Accident prevention and crisis research center, emergency organization, ShahidSadoughi University of Medical Sciences, Yazd, Iran
4- Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of public health, ShahidSadoughi University of Medical Sciences, Yazd, Iran , mhlotfi56359@gmail.com
Abstract:   (1272 Views)
Introduction: The World Health Organization on March 11, 2020 declared the outbreak of severe acute respiratory syndrome Corona virus 2 disease (COVID-19) a pandemic situation. The main aim of this study was investigating mortality of COVID 19 by considering chronic diseases.
Materials and methods: this study was conducted as a cross-sectional in which all confirmed cases were examined. The variables considered in this study were age, sex, diabetes mellitus, cancers, hypertension, heart diseases, kidney diseases, and liver diseases. Independent sample t test, Chi-square and binary logistic regression were used to data analysis. All statistical analysis was done in SPSS 16 and significant level was set at 0.05.
Results: Out of 22849 PCR and CT scan tests, 16061 ones were positive. According to the confirmed cases, prevalence of COVID-19 was calculated about 0.019. Also hospital case fatality rate and mortality rate were calculated 156 and about 8.2 per 100000 respectively.
 Hypertension, and age had significant relationship with morbidity of COVID-19, in other hand, age (OR: 4.51, p<0.001), kidney diseases (OR: 1.84, p<0.001), diabetes mellitus (OR: 1.31, p<0.001), cancer (OR: 2.73, p<0.001), liver diseases (OR: 2.27, p<0.001) had impact on mortality of covid-19. Population Attributable Fraction (PAF) showed that diabetes mellitus, cancers, kidney diseases, and liver diseases had 4.2, 2.4, 1.3, and 0.2 percent, respectively.
Conclusion: age and some underlying diseases increase odds of death due to COVID-19. It seems that preventing high-risk people from being infected is an effective solution to reduce COVID-19 death rate. To do this, health protocols need to be implemented more seriously for these sensitive groups.

Full-Text [PDF 90 kb]   (431 Downloads) |   |   Full-Text (HTML)  (210 Views)  
Review: Research | Subject: Epidemiology
Received: 2022/04/20 | Accepted: 2022/06/20 | Published: 2022/07/5

1. Hosseini S, Bahrevar V, Rahmanian V, Hazar N. Fear of COVID 19 Pandemic: A case study in Iran. Pakistan Journal of Medical and Health Sciences. 2020;14(2):484-7.
2. Hosseini S, Mohsenpour MA, Bahrevar V, Rahmanian V, Hazar N. Which information sources do people choose during the COVID-19 pandemic: Mass media or social media? A survey in Iran. Pakistan Journal of Medical and Health Sciences. 2020;14(3):1562-5.
3. Organization WH. Coronavirus disease (‎‎ COVID-19)‎‎: weekly epidemiological update. 2020.
4. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal. 2020;55(5). [DOI:10.1183/13993003.01227-2020]
5. Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1017-25. [DOI:10.1016/j.dsx.2020.06.064]
6. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN comprehensive clinical medicine. 2020:1-8. [DOI:10.1007/s42399-020-00363-4]
7. Ye C, Zhang S, Zhang X, Cai H, Gu J, Lian J, et al. Impact of comorbidities on patients with COVID‐19: A large retrospective study in Zhejiang, China. Journal of Medical Virology. 2020;92(11):2821-9. [DOI:10.1002/jmv.26183]
8. Cho SI, Yoon S, Lee H-J. Impact of comorbidity burden on mortality in patients with COVID-19: a retrospective analysis of the Korean health insurance database. 2020. [DOI:10.21203/rs.3.rs-54298/v1]
9. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;323(16):1574-81. [DOI:10.1001/jama.2020.5394]
10. Rosenbaum L. Facing Covid-19 in Italy-ethics, logistics, and therapeutics on the epidemic's front line. New England Journal of Medicine. 2020;382(20):1873-5. [DOI:10.1056/NEJMp2005492]
11. Organization WH. Islamic Republic of Iran country health profile 2020
12. Daneshpazhooh M, Mahmoudi H. COVID-19: The experience from Iran. Clinics in Dermatology. 2020. [DOI:10.1016/j.clindermatol.2020.12.009]
13. Peykari N, Eybpoosh S, Safikhani H, Haghdoost AA, Tabatabaei-Malazy O, Larijani B. Non-communicable Diseases and COVID-19; a double-edged sword A Special Communication from IRAN. Journal of Diabetes & Metabolic Disorders. 2020:1-5. [DOI:10.1007/s40200-020-00683-1]
14. Yanez ND, Weiss NS, Romand J-A, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1-7. [DOI:10.1186/s12889-020-09826-8]
15. Tian Y, Qiu X, Wang C, Zhao J, Jiang X, Niu W, et al. Cancer associates with risk and severe events of COVID‐19: A systematic review and meta‐analysis. International journal of cancer. 2021;148(2):363-74. [DOI:10.1002/ijc.33213]
16. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049. [DOI:10.18632/aging.103000]
17. Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A, et al. Comorbidity assessment is essential during COVID-19 treatment. Frontiers in physiology. 2020;11. [DOI:10.3389/fphys.2020.00984]
18. Lotfi MH, Saadati H, Afzali M. Prevalence of diabetes in people aged≥ 30 years: the results of screen-ing program of Yazd Province, Iran, in 2012. Journal of research in health sciences. 2013;14(1):88-92.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.

© 2024 CC BY 4.0 | Journal of Community Health Research

Designed & Developed by : Yektaweb